Full Text View
Tabular View
No Study Results Posted
Related Studies
Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in Liver Transplant Recipients (CAPSIL)
This study is currently recruiting participants.
Verified February 2013 by University of Pittsburgh
Study NCT01552369   Information provided by University of Pittsburgh

First Received on March 2, 2012.   Last Updated on February 1, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cytomegalovirus [CMV] Disease
Interventions listed in this trial
Preemptive Therapy
Prophylaxis with Valganciclovir
Additional drug interventions recognized in this trial
Ganciclovir
Valganciclovir
More general drug interventions related to this trial
Anti-Infective Agents
Antiviral Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
University of Pittsburgh
National Institutes of Health (NIH)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services